{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:51Z","timestamp":1790208051755,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.celrep.2019.08.105","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T10:32:28Z","timestamp":1570530748000},"page":"249-257.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Reduction of Global H3K27me3 Enhances HER2\/ErbB2 Targeted Therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Alison","family":"Hirukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarey","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Rennhack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Swiatnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Sanguin-Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilia","family":"Daldoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran R.","family":"Andrechek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay N.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Varadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2019.08.105_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI69736","article-title":"Harnessing the potential of epigenetic therapy to target solid tumors","volume":"124","author":"Ahuja","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2019.08.105_bib2","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1073\/pnas.97.7.3444","article-title":"Amplification of the neu\/erbB2-oncogene in a mouse model of mammary tumorigenesis","volume":"97","author":"Andrechek","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2019.08.105_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2019.08.105_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2019.08.105_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.celrep.2019.08.105_bib8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2015.10.020","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"164","author":"Chiappinelli","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib9","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining Epigenetic and Immunotherapy to Combat Cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2019.08.105_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in\u00a0vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1084\/jem.20141499","article-title":"Coupling of T\u00a0cell receptor specificity to natural killer T\u00a0cell development by bivalent histone H3 methylation","volume":"212","author":"Dobenecker","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm1764","article-title":"Stromal gene expression predicts clinical outcome in breast cancer","volume":"14","author":"Finak","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib13","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.molimm.2009.02.033","article-title":"Demethylating treatment suppresses natural killer cell cytolytic activity","volume":"46","author":"Gao","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.celrep.2019.08.105_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00018-017-2454-8","article-title":"Silencing of endogenous retroviruses by heterochromatin","volume":"74","author":"Groh","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.celrep.2019.08.105_bib15","first-page":"954","article-title":"Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease","volume":"12","author":"Guy","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.celrep.2019.08.105_bib16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.molonc.2012.06.002","article-title":"Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes","volume":"6","author":"Holm","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.celrep.2019.08.105_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1101\/gr.125872.111","article-title":"Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer","volume":"22","author":"Hon","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.celrep.2019.08.105_bib18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/19420862.2018.1486946","article-title":"Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody","volume":"10","author":"Huang","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.celrep.2019.08.105_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.molcel.2016.10.021","article-title":"An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences","volume":"64","author":"Ishak","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2019.08.105_bib22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.onc.1207200","article-title":"Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines","volume":"23","author":"Kauraniemi","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2019.08.105_bib23","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib24","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2019.08.105_bib25","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2019.08.105_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.celrep.2019.08.105_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1101\/gad.544410","article-title":"Polycomb complexes act redundantly to repress genomic repeats and genes","volume":"24","author":"Leeb","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2019.08.105_bib28","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2019.08.105_bib29","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2019.08.105_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clbc.2014.07.010","article-title":"Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer","volume":"15","author":"Mayer","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.celrep.2019.08.105_bib31","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-04-2476","article-title":"Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma","volume":"11","author":"Mimura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2019.08.105_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fimmu.2018.00617","article-title":"Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2\/3 Expression","volume":"9","author":"Niu","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2019.08.105_bib33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.celrep.2019.08.105_bib34","doi-asserted-by":"crossref","first-page":"e1466768","DOI":"10.1080\/2162402X.2018.1466768","article-title":"Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer","volume":"7","author":"Park","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.celrep.2019.08.105_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2019.08.105_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-med-042513-015127","article-title":"Targeting HER2 for the treatment of breast cancer","volume":"66","author":"Rimawi","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2019.08.105_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib41","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/emboj\/18.8.2149","article-title":"Elevated expression of activated forms of Neu\/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer","volume":"18","author":"Siegel","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.celrep.2019.08.105_bib42","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-019-10681-4","article-title":"An ErbB2\/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2019.08.105_bib43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I Interferon in Chronic Virus Infection and Cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.celrep.2019.08.105_bib44","first-page":"1720","article-title":"Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Spiridon","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2019.08.105_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS398","article-title":"A phase 1b\/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Taplin","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2019.08.105_bib46","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.4049\/jimmunol.1302943","article-title":"Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice","volume":"192","author":"Tong","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.celrep.2019.08.105_bib47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","article-title":"The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells","volume":"39","author":"Tumes","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2019.08.105_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc2127","article-title":"Insights from transgenic mouse models of ERBB2-induced breast cancer","volume":"7","author":"Ursini-Siegel","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2019.08.105_bib49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/emboj.2008.22","article-title":"ShcA signalling is essential for tumour progression in mouse models of human breast cancer","volume":"27","author":"Ursini-Siegel","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.celrep.2019.08.105_bib50","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","article-title":"Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines","volume":"133","author":"Vance","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.celrep.2019.08.105_bib51","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-15-2021","article-title":"Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer","volume":"22","author":"Varadan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2019.08.105_bib52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ijc.29808","article-title":"Brief-exposure to preoperative bevacizumab reveals a TGF-\u03b2 signature predictive of response in HER2-negative breast cancers","volume":"138","author":"Varadan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.celrep.2019.08.105_bib53","doi-asserted-by":"crossref","first-page":"619","DOI":"10.15252\/embr.201643237","article-title":"A non-canonical function of Ezh2 preserves immune homeostasis","volume":"18","author":"Vasanthakumar","year":"2017","journal-title":"EMBO Rep."},{"key":"10.1016\/j.celrep.2019.08.105_bib54","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.bjc.6605310","article-title":"Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma","volume":"101","author":"V\u00e9gran","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2019.08.105_bib55","doi-asserted-by":"crossref","first-page":"R87","DOI":"10.7554\/eLife.11418","article-title":"An epigenetic switch ensures transposon repression upon dynamic loss of DNA methylation in embryonic stem cells","volume":"5","author":"Walter","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2019.08.105_bib56","doi-asserted-by":"crossref","first-page":"56802","DOI":"10.18632\/oncotarget.18063","article-title":"Decitabine inhibits T\u00a0cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2019.08.105_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1749-6632.2010.05782.x","article-title":"Primary trastuzumab resistance: new tricks for an old drug","volume":"1210","author":"Wilken","year":"2010","journal-title":"Ann. N Y Acad. Sci."},{"issue":"15_suppl","key":"10.1016\/j.celrep.2019.08.105_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e12511","article-title":"Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion","volume":"37","author":"Yadav","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2019.08.105_bib59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","article-title":"Targeting the tumor microenvironment with interferon-\u03b2 bridges innate and adaptive immune responses","volume":"25","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2019.08.105_bib60","doi-asserted-by":"crossref","first-page":"15988","DOI":"10.1073\/pnas.1521740112","article-title":"Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity","volume":"112","author":"Yin","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2019.08.105_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2014.12.012","article-title":"Viral RNA detection by RIG-I-like receptors","volume":"32","author":"Yoneyama","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.celrep.2019.08.105_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/exmp.1999.2266","article-title":"Shared antigenic epitopes and pathobiological functions of anti-p185(her2\/neu) monoclonal antibodies","volume":"67","author":"Zhang","year":"1999","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.celrep.2019.08.105_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ni.3313","article-title":"Cancer mediates effector T\u00a0cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction","volume":"17","author":"Zhao","year":"2016","journal-title":"Nat. Immunol."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124719311672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124719311672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:43:30Z","timestamp":1761907410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124719311672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2211124719311672"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2019.08.105","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736722079.793566622","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.736722079.793568119","asserted-by":"object"}]},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of Global H3K27me3 Enhances HER2\/ErbB2 Targeted Therapy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2019.08.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors.","name":"copyright","label":"Copyright"}]}}